Symbols / SEPN Stock $31.03 +0.05% Septerna, Inc.

Healthcare • Biotechnology • United States • NGM
SEPN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Jeffrey T. Finer M.D., Ph.D.
Exch · Country NGM · United States
Market Cap 1.40B
Enterprise Value 1.07B
Income -36.04M
Sales 72.25M
FCF (ttm) 24.01M
Book/sh 8.52
Cash/sh 7.71
Employees 130
Insider 10d —
IPO Oct 25, 2024
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -11.67
PEG —
P/S 19.35
P/B 3.64
P/C —
EV/EBITDA -16.13
EV/Sales 14.86
Quick Ratio 4.63
Current Ratio 4.71
Debt/Eq 6.10
LT Debt/Eq —
EPS (ttm) -0.80
EPS next Y -2.66
EPS Growth —
Revenue Growth 120.11%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-10
Earnings (prior) 2026-05-11
ROA -8.49%
ROE -9.26%
ROIC —
Gross Margin 100.00%
Oper. Margin -50.14%
Profit Margin -49.88%
Shs Outstand 45.08M
Shs Float 23.12M
Insider Own 3.17%
Instit Own 102.63%
Short Float 11.47%
Short Ratio 8.59
Short Interest 2.62M
52W High 32.63
vs 52W High -4.92%
52W Low 9.85
vs 52W Low 214.91%
Beta —
Impl. Vol. 71.19%
Rel Volume 0.26
Avg Volume 312.06K
Volume 80.51K
Target (mean) $45.00
Tgt Median $43.00
Tgt Low $35.00
Tgt High $60.00
# Analysts 8
Recom Strong_buy
Prev Close $31.01
Price $31.02
Change 0.05%
About

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$45.00
Mean price target
2. Current target
$31.03
Latest analyst target
3. DCF / Fair value
$9.59
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$31.03
Low
$35.00
High
$60.00
Mean
$45.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-06-08 main Raymond James Strong Buy → Strong Buy $53
2026-05-13 reit HC Wainwright & Co. Buy → Buy $40
2026-04-14 reit HC Wainwright & Co. Buy → Buy $40
2026-03-24 main JP Morgan Overweight → Overweight $38
2026-03-11 main Truist Securities Buy → Buy $35
2026-03-03 main Wells Fargo Overweight → Overweight $48
2026-03-02 main HC Wainwright & Co. Buy → Buy $40
2026-01-20 main HC Wainwright & Co. Buy → Buy $35
2025-12-23 init Jones Trading — → Buy $43
2025-12-19 init Raymond James — → Strong Buy $38
2025-12-15 init Truist Securities — → Buy $34
2025-11-14 up Wells Fargo Equal-Weight → Overweight $28
2025-11-11 main HC Wainwright & Co. Buy → Buy $30
2025-09-05 reit Cantor Fitzgerald Overweight → Overweight $25
2025-08-21 reit HC Wainwright & Co. Buy → Buy $26
2025-06-23 init HC Wainwright & Co. — → Buy $26
2025-05-16 main Cantor Fitzgerald Overweight → Overweight $25
2025-05-16 main Wells Fargo Equal-Weight → Equal-Weight $18
2025-03-28 main Wells Fargo Equal-Weight → Equal-Weight $11
2025-02-18 down Wells Fargo Overweight → Equal-Weight $14
News
RSS: Latest SEPN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-06-01 SHAIKHLY SAMIRA Officer — 5,935 $1.55 $11,111
2026-06-01 SHAIKHLY SAMIRA Officer — 5,935 $27.78 $171,682
2026-05-26 SHAIKHLY SAMIRA Officer — 11,798 $6.81 $80,344
2026-05-26 SHAIKHLY SAMIRA Officer — 11,798 $30.06 $354,656
2026-04-15 BHATT ELIZABETH President — 4,000 $6.81 $27,240
2026-04-15 BHATT ELIZABETH President — 4,000 $23.76 $97,343
2026-03-02 SHAIKHLY SAMIRA Officer — 70,453 $1.55 $129,456
2026-03-02 SHAIKHLY SAMIRA Officer — 70,453 $27.51 $1,979,838
2026-02-18 BHATT ELIZABETH President — 4,000 $6.81 $27,240
2026-02-18 BHATT ELIZABETH President — 4,000 $28.46 $115,860
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
45.95
+4174.51%
1.07
+611.92%
0.15
0.00
Operating Revenue
45.95
+4174.51%
1.07
+611.92%
0.15
0.00
Operating Expense
126.75
+54.76%
81.90
+79.20%
45.70
+63.41%
27.97
Research And Development
97.58
+49.35%
65.34
+81.60%
35.98
+63.21%
22.04
Selling General And Administration
29.16
+76.10%
16.56
+70.35%
9.72
+64.14%
5.92
General And Administrative Expense
29.16
+76.10%
16.56
+70.35%
9.72
+64.14%
5.92
Other Gand A
29.16
+76.10%
16.56
+70.35%
9.72
+64.14%
5.92
Total Expenses
126.75
+54.76%
81.90
+79.20%
45.70
+63.41%
27.97
Operating Income
-80.80
+0.03%
-80.82
-77.44%
-45.55
-62.87%
-27.97
Total Operating Income As Reported
-68.30
+15.50%
-80.82
-3995.08%
2.08
+107.42%
-27.97
EBITDA
-79.19
+0.29%
-79.42
-77.67%
-44.70
-63.21%
-27.39
Normalized EBITDA
-91.69
-15.45%
-79.42
+13.98%
-92.33
-237.08%
-27.39
Reconciled Depreciation
1.60
+14.49%
1.40
+65.21%
0.85
+46.97%
0.58
EBIT
-80.80
+0.03%
-80.82
-77.44%
-45.55
-62.87%
-27.97
Total Unusual Items
12.50
0.00
-100.00%
47.62
0.00
Total Unusual Items Excluding Goodwill
12.50
0.00
-100.00%
47.62
0.00
Special Income Charges
12.50
0.00
-100.00%
47.62
0.00
Net Income
-48.88
+31.92%
-71.80
-1817.66%
4.18
+115.10%
-27.68
Pretax Income
-48.87
+32.41%
-72.30
-1584.21%
4.87
+117.60%
-27.68
Net Non Operating Interest Income Expense
19.53
+126.65%
8.62
+209.30%
2.79
+857.39%
0.29
Net Interest Income
19.53
+126.65%
8.62
+209.30%
2.79
+857.39%
0.29
Interest Income Non Operating
19.53
+126.65%
8.62
+209.30%
2.79
+857.39%
0.29
Interest Income
19.53
+126.65%
8.62
+209.30%
2.79
+857.39%
0.29
Other Income Expense
12.40
+13877.78%
-0.09
-100.19%
47.63
—
Other Non Operating Income Expenses
-0.10
-11.11%
-0.09
-1000.00%
0.01
—
Tax Provision
0.01
+102.41%
-0.50
-172.07%
0.69
0.00
Tax Rate For Calcs
0.00
-100.00%
0.00
-95.07%
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
-100.00%
6.76
0.00
Net Income Including Noncontrolling Interests
-48.88
+31.92%
-71.80
-1817.66%
4.18
+115.10%
-27.68
Net Income From Continuing Operation Net Minority Interest
-48.88
+31.92%
-71.80
-1817.66%
4.18
+115.10%
-27.68
Net Income From Continuing And Discontinued Operation
-48.88
+31.92%
-71.80
-1817.66%
4.18
+115.10%
-27.68
Net Income Continuous Operations
-48.88
+31.92%
-71.80
-1817.66%
4.18
+115.10%
-27.68
Normalized Income
-61.38
+14.51%
-71.80
-95.73%
-36.68
-32.54%
-27.68
Net Income Common Stockholders
-48.88
+31.92%
-71.80
-12762.79%
0.57
+102.05%
-27.68
Otherunder Preferred Stock Dividend
—
0.00
-100.00%
3.61
0.00
Diluted EPS
-1.10
+84.85%
-7.26
-25063.04%
0.03
+102.05%
-1.42
Basic EPS
-1.10
+84.85%
-7.26
-25063.04%
0.03
+102.05%
-1.42
Basic Average Shares
44.26
+347.46%
9.89
-49.27%
19.50
+0.00%
19.50
Diluted Average Shares
44.26
+347.46%
9.89
-49.27%
19.50
+0.00%
19.50
Diluted NI Availto Com Stockholders
-48.88
+31.92%
-71.80
-11514.63%
0.63
+102.27%
-27.68
Average Dilution Earnings
—
—
0.06
—
Gain On Sale Of PPE
12.50
0.00
-100.00%
47.62
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
596.19
+30.58%
456.55
+248.87%
130.87
+262.32%
36.12
Current Assets
410.96
+15.17%
356.82
+216.68%
112.68
+253.33%
31.89
Cash Cash Equivalents And Short Term Investments
391.09
+11.45%
350.92
+296.60%
88.48
+189.09%
30.61
Cash And Cash Equivalents
120.72
-49.32%
238.20
+169.20%
88.48
+189.09%
30.61
Cash Equivalents
—
—
86.57
+192.41%
29.61
Cash Financial
—
—
1.91
+90.90%
1.00
Other Short Term Investments
270.37
+139.84%
112.73
0.00
—
Receivables
13.74
+1122.42%
1.12
-95.06%
22.78
0.00
Accounts Receivable
10.36
+5956.14%
0.17
+13.25%
0.15
0.00
Other Receivables
—
—
22.62
—
Accrued Interest Receivable
3.38
+255.09%
0.95
—
—
Prepaid Assets
4.98
+9.81%
4.54
+241.97%
1.33
+22.98%
1.08
Other Current Assets
1.15
+382.01%
0.24
+159.78%
0.09
-54.90%
0.20
Total Non Current Assets
185.22
+85.72%
99.73
+448.30%
18.19
+330.10%
4.23
Net PPE
25.93
-9.62%
28.69
+66.94%
17.19
+453.53%
3.10
Gross PPE
30.29
-4.23%
31.62
+68.12%
18.81
+381.91%
3.90
Accumulated Depreciation
-4.35
-48.58%
-2.93
-80.58%
-1.62
-103.26%
-0.80
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
1.62
+0.00%
1.62
+74.33%
0.93
+303.03%
0.23
Construction In Progress
0.11
0.00
—
—
Other Properties
27.84
-4.93%
29.28
+67.43%
17.49
+376.28%
3.67
Leases
0.72
+0.00%
0.72
+84.32%
0.39
0.00
Investments And Advances
157.57
+125.53%
69.87
0.00
—
Other Non Current Assets
1.72
+46.84%
1.17
+16.97%
1.00
-10.85%
1.12
Total Liabilities Net Minority Interest
214.26
+486.90%
36.51
-78.43%
169.24
+110.71%
80.32
Current Liabilities
86.93
+576.56%
12.85
+85.84%
6.91
+24.73%
5.54
Payables And Accrued Expenses
16.38
+141.16%
6.79
+75.25%
3.88
+25.93%
3.08
Payables
10.28
+221.34%
3.20
+12.80%
2.84
-7.62%
3.07
Accounts Payable
10.28
+221.34%
3.20
+21.35%
2.64
-14.13%
3.07
Current Accrued Expenses
6.09
+69.70%
3.59
+245.95%
1.04
+17200.00%
0.01
Pensionand Other Post Retirement Benefit Plans Current
5.92
+43.50%
4.13
+39.78%
2.95
+73.15%
1.71
Total Tax Payable
—
0.00
-100.00%
0.20
0.00
Income Tax Payable
—
0.00
-100.00%
0.20
0.00
Current Debt And Capital Lease Obligation
2.21
+19.50%
1.85
—
0.71
Current Capital Lease Obligation
2.21
+19.50%
1.85
0.00
-100.00%
0.71
Current Deferred Liabilities
62.27
0.00
—
—
Current Deferred Revenue
62.27
0.00
—
—
Other Current Liabilities
0.15
+89.74%
0.08
-8.24%
0.09
+70.00%
0.05
Total Non Current Liabilities Net Minority Interest
127.33
+438.21%
23.66
-85.43%
162.33
+117.08%
74.78
Long Term Debt And Capital Lease Obligation
21.41
-9.36%
23.62
+88.01%
12.57
0.00
Long Term Capital Lease Obligation
21.41
-9.36%
23.62
+88.01%
12.57
0.00
Non Current Deferred Liabilities
105.92
0.00
—
—
Non Current Deferred Revenue
105.92
0.00
—
—
Other Non Current Liabilities
—
0.03
-93.96%
0.55
+557.83%
0.08
Preferred Securities Outside Stock Equity
—
0.00
-100.00%
149.22
+99.77%
74.69
Stockholders Equity
381.93
-9.08%
420.05
+1194.61%
-38.37
+13.18%
-44.20
Common Stock Equity
381.93
-9.08%
420.05
+1194.61%
-38.37
+13.18%
-44.20
Capital Stock
0.04
+2.27%
0.04
+1366.67%
0.00
+0.00%
0.00
Common Stock
0.04
+2.27%
0.04
+1366.67%
0.00
+0.00%
0.00
Preferred Stock
0.00
0.00
0.00
—
Share Issued
44.81
+0.86%
44.42
+5.76%
42.00
+0.00%
42.00
Ordinary Shares Number
44.81
+0.86%
44.42
+5.76%
42.00
+0.00%
42.00
Additional Paid In Capital
548.52
+1.89%
538.32
+6465.69%
8.20
+25.14%
6.55
Retained Earnings
-167.25
-41.29%
-118.37
-154.15%
-46.58
+8.24%
-50.76
Gains Losses Not Affecting Retained Earnings
0.62
+1001.79%
0.06
0.00
—
Other Equity Adjustments
0.62
+1001.79%
0.06
—
—
Total Equity Gross Minority Interest
381.93
-9.08%
420.05
+1194.61%
-38.37
+13.18%
-44.20
Total Capitalization
381.93
-9.08%
420.05
+1194.61%
-38.37
+13.18%
-44.20
Working Capital
324.03
-5.80%
343.98
+225.23%
105.76
+301.43%
26.35
Invested Capital
381.93
-9.08%
420.05
+1194.61%
-38.37
+13.18%
-44.20
Total Debt
23.62
-7.27%
25.48
+102.74%
12.57
+1669.86%
0.71
Capital Lease Obligations
23.62
-7.27%
25.48
+102.74%
12.57
+1669.86%
0.71
Net Tangible Assets
381.93
-9.08%
420.05
+1194.61%
-38.37
+13.18%
-44.20
Tangible Book Value
381.93
-9.08%
420.05
+1194.61%
-38.37
+13.18%
-44.20
Available For Sale Securities
157.57
+125.53%
69.87
—
—
Investmentin Financial Assets
157.57
+125.53%
69.87
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
110.19
+263.32%
-67.47
-74.24%
-38.72
-66.17%
-23.30
Cash Flow From Continuing Operating Activities
110.19
+263.32%
-67.47
-74.24%
-38.72
-66.17%
-23.30
Net Income From Continuing Operations
-48.88
+31.92%
-71.80
-1817.66%
4.18
+115.10%
-27.68
Depreciation Amortization Depletion
1.60
+14.49%
1.40
+65.21%
0.85
+46.97%
0.58
Depreciation And Amortization
1.60
+14.49%
1.40
+65.21%
0.85
+46.97%
0.58
Other Non Cash Items
2.16
+51.19%
1.43
+70.61%
0.84
+57.92%
0.53
Stock Based Compensation
8.48
+168.91%
3.15
+94.57%
1.62
+6.58%
1.52
Deferred Tax
0.00
+100.00%
-0.49
-200.00%
0.49
0.00
Deferred Income Tax
0.00
+100.00%
-0.49
-200.00%
0.49
0.00
Operating Gains Losses
-12.50
—
-47.62
—
Gain Loss On Sale Of PPE
—
—
0.03
0.00
Change In Working Capital
162.78
+65535.89%
0.25
-73.22%
0.93
-46.96%
1.75
Change In Receivables
-10.19
-50825.00%
-0.02
+86.75%
-0.15
0.00
Changes In Account Receivables
-10.19
-50825.00%
-0.02
+86.75%
-0.15
0.00
Change In Prepaid Assets
-3.78
+12.01%
-4.30
-3059.56%
-0.14
+86.73%
-1.02
Change In Payables And Accrued Expense
10.96
+155.70%
4.29
+135.81%
1.82
-41.35%
3.10
Change In Accrued Expense
4.36
+22.31%
3.56
+44.23%
2.47
+79.84%
1.37
Change In Payable
6.60
+813.28%
0.72
+210.72%
-0.65
-137.83%
1.73
Change In Account Payable
6.60
+813.28%
0.72
+210.72%
-0.65
-137.83%
1.73
Change In Other Working Capital
166.34
+37028.35%
0.45
+158.18%
-0.77
-34.38%
-0.57
Change In Other Current Assets
-0.55
-225.88%
-0.17
-203.03%
0.17
-32.38%
0.24
Investing Cash Flow
-229.35
-42.81%
-160.60
-825.97%
22.12
+1816.21%
-1.29
Cash Flow From Continuing Investing Activities
-229.35
-42.81%
-160.60
-825.97%
22.12
+1816.21%
-1.29
Net PPE Purchase And Sale
-0.52
+75.37%
-2.10
+26.93%
-2.88
-123.27%
-1.29
Purchase Of PPE
-0.52
+75.37%
-2.10
+26.93%
-2.88
-123.27%
-1.29
Capital Expenditure
-0.52
+75.37%
-2.10
+26.93%
-2.88
-123.27%
-1.29
Net Investment Purchase And Sale
-241.33
-33.25%
-181.12
0.00
—
Purchase Of Investment
-450.95
-111.33%
-213.39
0.00
—
Sale Of Investment
209.62
+549.57%
32.27
0.00
—
Net Other Investing Changes
12.50
-44.75%
22.62
-9.50%
25.00
—
Financing Cash Flow
1.69
-99.55%
377.78
+406.95%
74.52
+147.98%
30.05
Cash Flow From Continuing Financing Activities
1.69
-99.55%
377.78
+406.95%
74.52
+147.98%
30.05
Net Common Stock Issuance
-0.00
-100.00%
302.79
+30278800.00%
-0.00
—
Common Stock Payments
-0.00
+0.00%
-0.00
+0.00%
-0.00
—
Repurchase Of Capital Stock
-0.00
+0.00%
-0.00
+0.00%
-0.00
—
Proceeds From Stock Option Exercised
1.69
+3150.00%
0.05
0.00
-100.00%
0.08
Changes In Cash
-117.47
-178.47%
149.71
+158.49%
57.92
+960.98%
5.46
Beginning Cash Position
239.10
+167.49%
89.39
+184.05%
31.47
+20.99%
26.01
End Cash Position
121.63
-49.13%
239.10
+167.49%
89.39
+184.05%
31.47
Free Cash Flow
109.67
+257.63%
-69.57
-67.24%
-41.60
-69.16%
-24.59
Income Tax Paid Supplemental Data
0.00
-100.00%
0.23
+209.33%
0.07
0.00
Amortization Of Securities
-3.45
-144.54%
-1.41
0.00
—
Common Stock Issuance
0.00
-100.00%
302.79
0.00
—
Issuance Of Capital Stock
0.00
-100.00%
377.73
+406.88%
74.52
+148.66%
29.97
Net Preferred Stock Issuance
0.00
-100.00%
74.94
+0.56%
74.52
+148.66%
29.97
Preferred Stock Issuance
0.00
-100.00%
74.94
+0.56%
74.52
+148.66%
29.97
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category